Too Old to Operate4d
Clinical Course and Prognosis of Long-Term Survivors of Hepatocellular Carcinoma.
This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.This retrospective cohort study used ...
Synthetic RIG-I-agonist RNA induces death of hepatocellular carcinoma cells
A new study in the Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic acid-inducible gene I ...
manilatimes11d
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology ...
EurekAlert!11d
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Monthly Prescribing Reference8d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Science Daily11d
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy. BMC Research Notes , 2024; 17 (1) DOI: 10.1186/s13104-024-07016-y Cite This Page : ...
Morningstar11d
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated ...